AstraZeneca stock heads into the open after a 0.93% gain

At the close on September 10, 2026, AstraZeneca stock finished at 11,758.0 pence in London, up 0.93%. The shares traded between 11,552.2 and 11,800.0 pence, with roughly 1.70 million shares changing hands as analysts reiterated diverging views on the name.

AstraZeneca stock closed at 11,758.0 pence on the London Stock Exchange on September 10, 2026, marking a 0.93% gain on the session. The shares moved between a day low of 11,552.2 pence and a day high of 11,800.0 pence, with around 1.70 million shares traded in London that day, per exchange data cited by Investing.com.

September 10, 2026 in numbers

AstraZeneca PLC (ISIN GB0009895292, LSE: AZN) saw its London-listed shares edge higher on September 10, 2026 as investors digested fresh analyst commentary on the stock. Historical data compiled by Investing.com for the London listing show a closing price of 11,758.0 pence, up 108.0 pence or 0.93% from the prior session, with an intraday range between 11,552.2 pence and 11,800.0 pence and reported volume of roughly 1.70 million shares. The same overview places the close comfortably above the day low and below the intraday high, underlining a relatively contained trading range on that date.

An article on AstraZeneca published by Ad-hoc-news on September 10, 2026 reported the shares trading around 11,658.0 pence in London, only modestly above Deutsche Bank’s reiterated price target of 11,500 pence and highlighting how the rally left the stock still close to that valuation benchmark. The same report, drawing on data from Proactive Investors and MarketScreener, noted that AstraZeneca’s London price action remained relatively muted despite new respiratory and oncology trial updates and that year-to-date performance had weakened, with the shares down several percent over recent weeks even as they inched higher in that particular session.

Today’s key factors for AstraZeneca

Looking into today’s session on September 11, 2026, market focus around AstraZeneca is shaped largely by the ongoing analyst debate on the stock rather than a single scheduled corporate event. Coverage cited by Ad-hoc-news on September 10, 2026 described how Berenberg reaffirmed a Buy rating and maintained a 160.00 pence target, while RBC also voiced support for the shares following updates in chronic obstructive pulmonary disease trials, even as other houses such as Deutsche Bank stayed cautious. Against that backdrop, investors today are likely to track any further clinical or regulatory headlines and new analyst notes, alongside broader moves in the FTSE 100 and global pharmaceuticals, as potential catalysts for AstraZeneca’s next leg of trading.